Aliases & Classifications for Meniere Disease

MalaCards integrated aliases for Meniere Disease:

Name: Meniere Disease 57 12 20 43 36 44 39 17 70
Meniere's Disease 12 20 43 42 15
Ménière's Disease 73 20 43 6
Otogenic Vertigo 12 43
Ménière Disease 43 32
Primary Endolymphatic Hydrops 43
Meniere's Syndrome 43
Ménière's Vertigo 43
Auditory Vertigo 43
Menieres Disease 54
Mnire's Vertigo 12
Vertigo, Aural 70
Aural Vertigo 43

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Miscellaneous:
incomplete penetrance
onset usually between 30 and 50 years of age
prevalence of 0.5 to 1 in 1,000

Inheritance:
autosomal dominant


HPO:

31
meniere disease:
Inheritance autosomal dominant inheritance
Onset and clinical course incomplete penetrance


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Ear diseases


External Ids:

Disease Ontology 12 DOID:9849
OMIM® 57 156000
KEGG 36 H01495
ICD9CM 34 386.0
MeSH 44 D008575
SNOMED-CT 67 194346003
ICD10 32 H81.0
MedGen 41 C0025281
UMLS 70 C0025281 C1527320

Summaries for Meniere Disease

MedlinePlus Genetics : 43 Ménière disease is a disorder of the inner ear that affects balance and hearing. This condition is characterized by sudden episodes of extreme dizziness (vertigo), a roaring sound in the ears (tinnitus), a feeling of pressure or fullness in the ears, and fluctuations in hearing. Episodes are often associated with nausea and vomiting, and they can severely disrupt activities of daily living.The episodes associated with Ménière disease generally last several hours. Studies suggest that episodes can be triggered by stress, tiredness (fatigue), emotional upset, illness, and dietary factors. The timing of these episodes is unpredictable; affected individuals may experience a cluster of episodes within a short period, followed by months or years without any symptoms.Ménière disease usually appears in adulthood, most often in a person's 40s or 50s. It is much less common in children and young adults. The symptoms of the disorder typically begin in one ear, although they may later involve both ears.Some people with Ménière disease have no symptoms of the disorder between episodes, particularly in the early stages of the disease. Over time, however, many affected individuals develop ongoing problems with unsteadiness, tinnitus, and a feeling of fullness in the ears. Additionally, permanent hearing loss eventually develops in many people with this disorder.

MalaCards based summary : Meniere Disease, also known as meniere's disease, is related to otosclerosis and branchiootic syndrome 1, and has symptoms including vertigo, tinnitus and snoring. An important gene associated with Meniere Disease is FAM136A (Family With Sequence Similarity 136 Member A), and among its related pathways/superpathways is Aquaporin-mediated transport. The drugs Sodium citrate and Nicotinamide have been mentioned in the context of this disorder. Affiliated tissues include bone, brain and eye, and related phenotypes are hearing impairment and vertigo

Disease Ontology : 12 A vestibular disease characterized by vertigo, low-pitched tinnitus and hearing loss.

GARD : 20 Meniere's disease is an abnormality of the inner ear. Signs and symptoms may include disabling vertigo or severe dizziness lasting from minutes to hours; tinnitus or a roaring sound in the ears; fluctuating hearing loss ; and the sensation of pressure or pain in the affected ear. A small percentage of people have drop attacks. The disorder usually affects only one ear, but some people develop symptoms in both ears many years after their initial diagnosis. Although the exact cause of Meniere's disease is unknown, the symptoms are thought to be associated with a change in fluid volume within a portion of the inner ear known as the labyrinth. Treatment may include medications or surgery depending on the severity of the condition.

OMIM® : 57 Meniere disease is a chronic illness characterized by intermittent episodes of vertigo lasting from minutes to hours, with fluctuating sensorineural hearing loss, tinnitus, and aural pressure (Sajjadi and Paparella, 2008). (156000) (Updated 05-Apr-2021)

MedlinePlus : 42 Meniere's disease is a disorder of the inner ear. It can cause severe dizziness, a roaring sound in your ears called tinnitus, hearing loss that comes and goes and the feeling of ear pressure or pain. It usually affects just one ear. It is a common cause of hearing loss. Attacks of dizziness may come on suddenly or after a short period of tinnitus or muffled hearing. Some people have single attacks of dizziness once in a while. Others may have many attacks close together over several days. Some people with Meniere's disease have "drop attacks" during which the dizziness is so bad they lose their balance and fall. Scientists don't yet know the cause. They think that it has to do with the fluid levels or the mixing of fluids in the canals of your inner ear. Doctors diagnose it based on a physical exam and your symptoms. A hearing test can check to see how it has affected your hearing. There is no cure. Treatments include medicines to control dizziness, limiting salt in your diet, and taking water pills. A device that fits into the outer ear and delivers air pulses to the middle ear can help. Severe cases may require surgery. NIH: National Institute on Deafness and Other Communication Disorders

KEGG : 36 Meniere disease is an inner ear disorder characterized by episodic vertigo attacks, sensorineural hearing loss, tinnitus, and aural fullness. Prevailing theories on its pathogenesis point to endolymphatic hydrops as one derangement responsible for producing dysfunction within the cochlea and peripheral vestibular apparatus. Although the familial clustering and the geographical and racial differences in incidence suggest a certain role for genetic factors in the development of Meniere disease, no convincing evidence for an association with any gene exists, at present.

Wikipedia : 73 Ménière's disease (MD) is a disorder of the inner ear that is characterized by episodes of feeling like... more...

Related Diseases for Meniere Disease

Diseases related to Meniere Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 248)
# Related Disease Score Top Affiliating Genes
1 otosclerosis 30.8 SLC26A4 GJB2 COCH
2 branchiootic syndrome 1 30.7 SLC26A4 OTOG MYO7A GJB2
3 labyrinthitis 30.3 SLC26A4 MYO7A GJB2 COCH
4 cogan syndrome 30.1 HSPA4 GJB2 COCH
5 viral labyrinthitis 30.0 GJB2 AQP6
6 intraocular pressure quantitative trait locus 30.0 SERPINA3 MIP COCH
7 deafness, autosomal dominant 15 29.8 MYO7A KCNQ4 FAM136A
8 inner ear disease 29.8 SLC26A4 MYO7A MIP KCNQ4 GJB2 COCH
9 deafness, autosomal dominant 6 29.5 SLC26A4 MYO7A KCNQ4 GJB2
10 sensorineural hearing loss 29.5 SLC26A4 MYO7A KCNQ4 KCNE1 HSPA8 HSPA4
11 deafness, autosomal dominant 9 29.3 SLC26A4 MYO7A KCNQ4 GJB2 FAM136A COCH
12 autosomal dominant non-syndromic sensorineural deafness type dfna 29.3 SLC26A4 MYO7A KCNQ4 GJB2 COCH
13 auditory system disease 29.1 SLC26A4 SERPINA3 OTOG MYO7A KCNQ4 HSPA8
14 peripheral vertigo 28.6 SLC26A4 OTOG MYO7A KCNQ4 KCNE3 KCNE1
15 vestibular disease 28.4 SLC26A4 OTOG MYO7A KCNQ4 KCNE3 KCNE1
16 active cochleovestibular meniere's disease 11.1
17 active vestibular meniere's disease 11.1
18 active cochlear meniere's disease 11.1
19 kanzaki disease 11.0
20 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
21 migraine with or without aura 1 10.3
22 superior semicircular canal dehiscence 10.3 SLC26A4 COCH
23 deafness, autosomal recessive 91 10.3 GJB2 COCH
24 facial paralysis 10.3
25 syphilis 10.3
26 deafness, autosomal dominant 3a 10.3 GJB2 COCH
27 deafness, autosomal dominant 16 10.3 KCNQ4 COCH
28 deafness, autosomal recessive 16 10.3 OTOG GJB2
29 neuroma 10.2
30 steroid-induced glaucoma 10.2 SERPINA3 COCH
31 deafness, autosomal recessive 8 10.2 SERPINA3 GJB2
32 deafness, autosomal recessive 77 10.2 SLC26A4 GJB2
33 pathologic nystagmus 10.2
34 deafness, autosomal dominant 28 10.2 KCNQ4 FAM136A COCH
35 sleep apnea 10.2
36 syncope 10.2
37 ear malformation 10.2 SLC26A4 GJB2
38 deafness, autosomal dominant 56 10.2 SLC26A4 GJB2 COCH
39 deafness, autosomal dominant 64 10.2 KCNQ4 GJB2
40 hereditary hearing loss and deafness 10.2 KCNE1 GJB2 COCH
41 long qt syndrome 5 10.2 KCNE3 KCNE1
42 autoimmune inner ear disease 10.2
43 head injury 10.2
44 headache 10.2
45 hearing loss, noise-induced 10.2
46 long qt syndrome 6 10.2 KCNE3 KCNE1
47 deafness, autosomal recessive 83 10.1 SLC26A4 MYO7A
48 nonsyndromic deafness 10.1 OTOG KCNQ4 GJB2
49 deafness, autosomal dominant 2b 10.1 KCNQ4 GJB2 COCH
50 deafness, autosomal dominant 2a 10.1 KCNQ4 GJB2 COCH

Comorbidity relations with Meniere Disease via Phenotypic Disease Network (PDN):


Active Vestibular Meniere's Disease Anxiety
Esophagitis Hypertension, Essential
Hypothyroidism Labyrinthitis
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Meniere Disease:



Diseases related to Meniere Disease

Symptoms & Phenotypes for Meniere Disease

Human phenotypes related to Meniere Disease:

31
# Description HPO Frequency HPO Source Accession
1 hearing impairment 31 HP:0000365
2 vertigo 31 HP:0002321
3 tinnitus 31 HP:0000360

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Head And Neck Ears:
tinnitus
vertigo, episodic
hearing impairment, sensorineural, fluctuating
aural fullness

Clinical features from OMIM®:

156000 (Updated 05-Apr-2021)

UMLS symptoms related to Meniere Disease:


vertigo; tinnitus; snoring; sore throat; coughing; vertigo/dizziness; equilibration disorder

MGI Mouse Phenotypes related to Meniere Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hearing/vestibular/ear MP:0005377 9.17 COCH GJB2 KCNE3 KCNQ4 MYO7A OTOG

Drugs & Therapeutics for Meniere Disease

Drugs for Meniere Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium citrate Approved, Investigational Phase 4 68-04-2
2
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
3
Diphenidol Approved, Investigational, Withdrawn Phase 4 972-02-1 3055
4
Tocopherol Approved, Investigational Phase 4 1406-66-2
5
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
6
Betahistine Approved, Investigational Phase 4 5638-76-6 2366
7
Montelukast Approved Phase 4 158966-92-8 5281040
8
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
9
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
12 Tocotrienol Investigational Phase 4 6829-55-6
13 Antioxidants Phase 4
14 Neurotransmitter Agents Phase 4
15 Vasodilator Agents Phase 4
16 Citrate Phase 4
17 Phosphodiesterase Inhibitors Phase 4
18 Sildenafil Citrate Phase 4 171599-83-0
19 Phosphodiesterase 5 Inhibitors Phase 4
20 Vitamin B9 Phase 4
21 Nutrients Phase 4
22 Trace Elements Phase 4
23 Micronutrients Phase 4
24 Antimetabolites Phase 4
25 Vitamin B Complex Phase 4
26 Vitamins Phase 4
27 Folate Phase 4
28 Tocotrienols Phase 4
29 Lipid Regulating Agents Phase 4
30 Tocopherols Phase 4
31 Nicotinic Acids Phase 4
32 Vitamin B3 Phase 4
33 Hypolipidemic Agents Phase 4
34
Histamine Phosphate Phase 4 51-74-1 65513
35 Anti-Asthmatic Agents Phase 4
36 Respiratory System Agents Phase 4
37 Leukotriene Antagonists Phase 4
38
Acyclovir Approved Phase 2, Phase 3 59277-89-3 2022
39
Lamotrigine Approved, Investigational Phase 3 84057-84-1 3878
40
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
41
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
42
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
43
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
44
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
45
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
46
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
48
Famciclovir Approved, Investigational Phase 3 104227-87-4 3324
49
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
50
Ebselen Investigational Phase 3 60940-34-3 3194

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study Of The Efficacy and Safety Of Sildenafil Given For The Acute Treatment Of Meniere's Disease Completed NCT00145483 Phase 4 Sildenafil
2 A Multicenter, Randomized, Open-label Clinical Study With a Concurrent Control Group to Assess the Effectiveness and Safety of Combined Therapy With Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets for Patients With Meniere's Disease Completed NCT02718846 Phase 4 Meniace;Isobide
3 Phase 3 Study of Efficacy of Local Overpressure Treatment for Meniere's Disease Completed NCT00831688 Phase 4
4 Effect of Stellate Ganglion Block on Meniere's Disease Completed NCT01574313 Phase 4 0.25mg, fludiazine;25mg cephadol@ (diphenidol);200mg kentons@ (tocopherol nicotinate).
5 A Double-Blind, Placebo-Controlled, Randomized, Clinical Study of the Effects of Betaserc® 24 mg (1 Tablet b.i.d Over 3 Months) on Vestibular Compensation Following Vestibular Neurotomy in Patients With Disabling Menière's Disease Completed NCT00160238 Phase 4 Betahistine 24 mg bid (Betaserc)
6 Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease Recruiting NCT04815187 Phase 4 Montelukast;Placebo
7 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease Terminated NCT02530931 Phase 4 Gadolinium
8 Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS) Terminated NCT02529475 Phase 4 Gadoteric acid
9 Assessment of Acyclovir Efficacy Versus Placebo in Controlling Vertigo Attacks of Patients With Meniere's Disease Visited in Amiralam Hospital Unknown status NCT01729767 Phase 2, Phase 3 Acyclovir;Placebo
10 Lamotrigine for Ménière's Disease: a Double-blind, Placebo-controlled Pilot Study Completed NCT02158585 Phase 3 Lamotrigine;Placebo
11 Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial Completed NCT00802529 Phase 2, Phase 3 Methylprednisolone;Gentamicin
12 A Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Completed NCT03664674 Phase 3 OTO-104;Placebo
13 A Random Controlled Clinical Trial:l Traditional Chinese Diaoshi Jifa Therapy of Meniere's Disease Completed NCT01454726 Phase 3
14 A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Completed NCT02612337 Phase 3 OTO-104;Placebo
15 Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes Recruiting NCT04218123 Phase 2, Phase 3 Venlafaxine;Placebo oral tablet
16 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005 Not yet recruiting NCT04677972 Phase 3 Ebselen;Placebo
17 A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Terminated NCT02768662 Phase 3 OTO-104
18 A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Terminated NCT02717442 Phase 3 OTO-104;Placebo
19 A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Terminated NCT02706730 Phase 3 OTO-104
20 Treatment of Hearing Fluctuation in Unilateral Meniere's Disease: A Randomized, Placebo-controlled Clinical Trial of Famciclovir Terminated NCT01526408 Phase 3 Famciclovir;Placebo
21 A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Menière's Disease Unknown status NCT01973114 Phase 2 Latanoprost
22 A 6-Month, Prospective, Randomized, Multicenter, Placebo-Controlled Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Followed by a 6-Month Open-Label Extension Completed NCT02265393 Phase 2 OTO-104;Placebo
23 Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease Completed NCT02603081 Phase 1, Phase 2 SPI-1005
24 A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2b Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Completed NCT01412177 Phase 2 OTO-104;Placebo
25 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease Completed NCT03325790 Phase 2 200mg SPI-1005 BID;400mg SPI-1005 BID
26 A Phase II Placebo Controlled Study of the Effects of Anakinra (Kineret) in Subjects With Corticosteroid-Resistant Meniere's Disease (CR-MD) and Corticosteroid-Resistant Autoimmune Inner Ear Disease Disease (CR-AIED) Recruiting NCT03587701 Phase 2 Anakinra 100Mg/0.67Ml Inj Syringe (Period 1);Placebo injection (Period 1);Anakinra 100Mg/0.67Ml Inj Syringe (Period 2);Placebo injection (Period 2)
27 Verification of the Efficacy / Safety of the Dual Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss (Pilot Study) Not yet recruiting NCT04766853 Phase 1, Phase 2 Dexamethasone;Hyaluronic acid
28 A 1-Year, Phase 2, Open-Label Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Terminated NCT02740387 Phase 2 OTO-104
29 A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 1B Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease Completed NCT01084525 Phase 1 OTO-104 (steroid) 3 mg;Placebo;OTO-104 (steroid) 12 mg
30 Multicentre, Open Label, Phase I Clinical Trial to Evaluate the Safety of APSLXR for the Treatment of Vertigo of Vestibular Origin or Meniere's Disease Not yet recruiting NCT04674735 Phase 1 APSLXR
31 Reduction of Plasma Vasopressin Level in Patients With Meniere's Disease Unknown status NCT01099046
32 Diagnostic Agreement of Electrophysiological Audiovestibular Examinations With Magnetic Resonance Imaging (MRI) of the Inner Ear in Revealing Endolymphatic Hydrops (EH) in Patients With Certain or Probable Meniere's Disease (MD) Unknown status NCT03215420
33 Consequence of Unilateral Vestibular Loss on Visual Abilities Unknown status NCT03581331
34 Transcutaneous Auricular Vagus Nerve Stimulation for the Treatment of Meniere Disease: a Pilot Study Completed NCT04686695
35 Vasopressin and V2 Receptor in Meniere's Disease Completed NCT00599560
36 Clinical Study of Endolymphatic Sac Drainage With or Without Steroids for Intractable Meniere's Disease Completed NCT00500474
37 Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent Completed NCT02080312 Magnevist (gadopentetate dimeglumine)
38 Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach Completed NCT02309099
39 Risk Factors for the Development of Bilateral Ménière's Disease and the Establishment of a National Ménière's Disease Registry. Recruiting NCT04438538
40 Non Enhanced Labyrinth Imaging for the Detection of Endolymphatic Hydrops in Meniere's Disease "NELI Study" Recruiting NCT04569175
41 Cochlear Implantation During Vestibular Schwannoma Removal or During Labyrinthectomy Surgery for Treatment of Meniere's Disease Recruiting NCT03795675
42 Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Dizziness Trial Recruiting NCT04026516
43 A Prospective, Randomized, Blinded, Placebo-controlled, Single Center, Efficacy Study of a Mastoid Device in Subjects With Ménière's Disease Enrolling by invitation NCT03520322
44 Imaging Endolymphatic Hydrops at 7T MRI: Validation of Internal Inner Ear Structures on T2w Imaging as Markers of Endolymphatic Hydrops and a Comparison of Diagnostic Outcomes With 3T MRI Not yet recruiting NCT04370366
45 Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection Not yet recruiting NCT04794842 Early Phase 1 Tetracaine 5% drops;Phenol 90% concentration
46 Diagnosing Endolymphatic Hydrops in Patients With Meniere Disease Using Magnetic Resonance Imaging With Intravenous Gadolinium Administration Withdrawn NCT02371798 Gadopentetate dimeglumine

Search NIH Clinical Center for Meniere Disease

Cochrane evidence based reviews: meniere disease

Genetic Tests for Meniere Disease

Anatomical Context for Meniere Disease

MalaCards organs/tissues related to Meniere Disease:

40
Bone, Brain, Eye, Cortex, Heart, Thyroid, Breast

Publications for Meniere Disease

Articles related to Meniere Disease:

(show top 50) (show all 2574)
# Title Authors PMID Year
1
Identification of two novel mutations in FAM136A and DTNA genes in autosomal-dominant familial Meniere's disease. 6 57 61
25305078 2015
2
Absence of COCH mutations in patients with Meniere disease. 57 54 61
14704763 2004
3
A novel missense variant in PRKCB segregates low-frequency hearing loss in an autosomal dominant family with Meniere's disease. 57 61
27329761 2016
4
Familial clustering and genetic heterogeneity in Meniere's disease. 61 57
23521103 2014
5
Meniere's disease. 57 61
18675691 2008
6
The cause (multifactorial inheritance) and pathogenesis (endolymphatic malabsorption) of Meniere's disease and its symptoms (mechanical and chemical). 61 57
4013733 1985
7
The Impact of the COVID-19 Pandemic on Follow-Ups for Vertigo/Dizziness Outpatients. 61 42
33295213 2021
8
Effects of an Intratympanic Injection of Dexamethasone Combined with Gentamicin on the Expression Level of Serum P0 Protein Antibodies in Patients with Meniere's Disease. 42 61
33263629 2020
9
Anticipation in Menière's disease. 57
7642988 1995
10
Occurrence of episodic vertigo and hearing loss in families. 57
5892598 1965
11
Vestibulo-ocular reflex tests may reflect unilateral Ménière disease progression: A cross-sectional study. 42
33350750 2020
12
Aquaporins as potential drug targets for Meniere's disease and its related diseases. 61 54
19096777 2009
13
Aquaporins and Meniere's disease. 61 54
16974147 2006
14
Validity of the Western blot immunoassay for heat shock protein-70 in associated and isolated immunorelated inner ear disease. 54 61
11889388 2002
15
Anti-heat shock protein 70 antibodies in Meniere's disease. 61 54
11224793 2001
16
Proteomics and the inner ear. 54 61
11790893 2001
17
Anti-heat shock protein 70 antibodies in Meniere's disease. 54 61
10983953 2000
18
Recognition of a dominant epitope in bovine heat-shock protein 70 in inner ear disease. 61 54
10201752 1999
19
Failure of elevated heat shock protein 70 antibodies to alter cochlear function in mice. 54 61
9508029 1998
20
Comparison of anti-heat shock protein 70 (anti-hsp70) and anti-68-kDa inner ear protein in the sera of patients with Meniere's disease. 61 54
9023247 1997
21
Which Inner Ear Disorders Lie Behind a Selective Posterior Semicircular Canal Hypofunction on Video Head Impulse Test? 61
33710996 2021
22
Identification of early-stage Meniere's disease as a cause of unilateral tinnitus. 61
33777120 2021
23
Peripheral Vestibular Disorders: Nationwide Evidence From Taiwan. 61
32621538 2021
24
Effect of advancing age on inter-frequency amplitude ratio of ocular vestibular evoked myogenic potentials. 61
33660579 2021
25
High level of IgE in acute low-tone sensorineural hearing loss: A predictor for recurrence and Meniere Disease transformation. 61
33429184 2021
26
The transcriptome characteristics of vestibular organs from delayed endolymphatic hydrops patients (Meniere's disease). 61
33655689 2021
27
In Response to Chronic Cerebrospinal Venous Insufficiency and Meniere's Disease: Interventional Versus Medical Therapy. 61
32579708 2021
28
In Reference to Chronic Cerebrospinal Venous Insufficiency and Meniere's Disease: Interventional Versus Medical Therapy. 61
32374415 2021
29
Regarding Chronic Cerebrospinal Venous Insufficiency and Meniere's Disease: Interventional Versus Medical Therapy. 61
32579709 2021
30
Which is the optimally defined vestibular cross-section to diagnose unilateral Meniere's disease with delayed post-gadolinium 3D fluid-attenuated inversion recovery MRI? 61
33449817 2021
31
Benign recurrent vestibulopathy: MRI and vestibular tests results in a series of 128 cases. 61
33547924 2021
32
Aquaporins and diseases pathogenesis: From trivial to undeniable involvements, a disease-based point of view. 61
33559160 2021
33
[Climatic variations and vertigo diseases in outpatients clinic of ENT]. 61
33540987 2021
34
Development of ebselen for the treatment of sensorineural hearing loss and tinnitus. 61
33678494 2021
35
Immunohistochemical location of Na+, K+-ATPase α1 subunit in the human inner ear. 61
33221698 2021
36
Relationship between Endolymphatic Hydrops and Symptoms of Meniere Disease in Acoustic Hearing. 61
33626533 2021
37
The value of 3D-real IR MRI with intravenous gadolinium injection in the diagnosis of suspected Meniere's disease in children. 61
33176531 2021
38
Letter to the editor: "Meniere's disease and migraine: more than a simple association". 61
33444906 2021
39
Diagnostic and therapeutic strategies for Meniere's disease of the Japan Society for Equilibrium Research. 61
33131962 2021
40
[Study of ocular vestibular evoked myogenic potentials in benign paroxysmal positional vertigo associated with Meniere's disease]. 61
33540992 2021
41
Positional Nystagmus after Acute Vertiginous Attack in Meniere's Disease. 61
33562076 2021
42
Dissociation of caloric and head impulse tests: a marker of Meniere's disease. 61
31222419 2021
43
Evolution of caloric responses during and between the attacks of Meniere's disease. 61
33611629 2021
44
Could ionic regulation disorders explain the overlap between meniere's disease and migraine? 61
33579883 2021
45
Imaging of endolymphatic hydrops on a vertigo attack of Meniere's disease. 61
33727752 2021
46
The characteristics of vHIT gain and PR score in peripheral vestibular disorders. 61
32930021 2021
47
Changing Paradigm for Vertigo/Dizziness Patients: a Retrospective Before-After Study from Tertiary Hospitals in Northwestern China. 61
33501533 2021
48
Genetics and the Individualized Therapy of Vestibular Disorders. 61
33613440 2021
49
Elevated ocular VEMP responses in the absence of a superior semicircular canal dehiscence. 61
33130534 2021
50
The dynamics of endolymphatic hydrops and vestibular disorders. 61
33459676 2021

Variations for Meniere Disease

ClinVar genetic disease variations for Meniere Disease:

6 (show all 12)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FAM136A NM_001329752.2(FAM136A):c.547C>T (p.Gln183Ter) SNV Pathogenic 140608 GRCh37: 2:70527974-70527974
GRCh38: 2:70300842-70300842
2 DTNA NM_001198938.2(DTNA):c.1963G>T (p.Val655Phe) SNV Likely pathogenic 140609 GRCh37: 18:32462094-32462094
GRCh38: 18:34882130-34882130
3 OTOG NM_001277269.2(OTOG):c.[421G>A] SNV Likely pathogenic 229094 rs552304627 GRCh37: 11:17574758-17574758
GRCh38: 11:17553211-17553211
4 OTOG NM_001277269.2(OTOG):c.[7667G>A] SNV Uncertain significance 227796 rs76461792 GRCh37: 11:17656672-17656672
GRCh38: 11:17635125-17635125
5 OTOG NM_001292063.2(OTOG):c.2203C>A (p.Pro735Thr) SNV Uncertain significance 816640 GRCh37: 11:17594747-17594747
GRCh38: 11:17573200-17573200
6 OTOG NM_001277269.2(OTOG):c.[6110C>T] SNV Uncertain significance 226902 rs61736002 GRCh37: 11:17632921-17632921
GRCh38: 11:17611374-17611374
7 OTOG NM_001277269.2(OTOG):c.[805G>A] SNV Uncertain significance 226914 rs61978648 GRCh37: 11:17578774-17578774
GRCh38: 11:17557227-17557227
8 OTOG NM_001277269.2(OTOG):c.[3719C>T] SNV Uncertain significance 229088 rs117005078 GRCh37: 11:17621218-17621218
GRCh38: 11:17599671-17599671
9 OTOG NM_001277269.2(OTOG):c.[4058G>A] SNV Uncertain significance 226891 rs145689709 GRCh37: 11:17627548-17627548
GRCh38: 11:17606001-17606001
10 OTOG NM_001277269.2(OTOG):c.[8405G>A] SNV Uncertain significance 226920 rs117315845 GRCh37: 11:17663747-17663747
GRCh38: 11:17642200-17642200
11 OTOG NM_001277269.2(OTOG):c.[4642C>T] SNV Likely benign 226894 rs117380920 GRCh37: 11:17631453-17631453
GRCh38: 11:17609906-17609906
12 OTOG NM_001277269.2(OTOG):c.[8526G>C] SNV Likely benign 226921 rs61997203 GRCh37: 11:17667139-17667139
GRCh38: 11:17645592-17645592

Expression for Meniere Disease

Search GEO for disease gene expression data for Meniere Disease.

Pathways for Meniere Disease

Pathways related to Meniere Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.34 MIP AVP AQP6 AQP2

GO Terms for Meniere Disease

Cellular components related to Meniere Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.93 SLC26A4 OTOG MIP KCNQ4 KCNE3 KCNE1
2 apical plasma membrane GO:0016324 9.17 SLC26A4 OTOG MYO7A MIP KCNE1 AQP6
3 voltage-gated potassium channel complex GO:0008076 9.13 KCNQ4 KCNE3 KCNE1

Biological processes related to Meniere Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.63 SLC26A4 MIP KCNQ4 GJB2 AQP6 AQP2
2 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.48 KCNE3 KCNE1
3 ventricular cardiac muscle cell action potential GO:0086005 9.46 KCNE3 KCNE1
4 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.43 KCNE3 KCNE1
5 potassium ion export across plasma membrane GO:0097623 9.4 KCNE3 KCNE1
6 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.37 KCNE3 KCNE1
7 membrane repolarization during action potential GO:0086011 9.32 KCNE3 KCNE1
8 gap junction-mediated intercellular transport GO:1990349 9.26 MIP GJB2
9 water transport GO:0006833 9.26 MIP AVP AQP6 AQP2
10 sensory perception of sound GO:0007605 9.17 SLC26A4 OTOG MYO7A KCNQ4 KCNE1 GJB2

Molecular functions related to Meniere Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 potassium channel activity GO:0005267 9.5 KCNQ4 KCNE3 KCNE1
2 voltage-gated potassium channel activity GO:0005249 9.43 KCNQ4 KCNE3 KCNE1
3 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.37 KCNE3 KCNE1
4 delayed rectifier potassium channel activity GO:0005251 9.33 KCNQ4 KCNE3 KCNE1
5 channel activity GO:0015267 9.13 MIP AQP6 AQP2
6 water channel activity GO:0015250 8.8 MIP AQP6 AQP2

Sources for Meniere Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....